Tetrahydroisoquinolines

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 1407 Experts worldwide ranked by ideXlab platform

Kevin R. Criscione - One of the best experts on this subject based on the ideXlab platform.

Gary L. Grunewald - One of the best experts on this subject based on the ideXlab platform.

Jesper L. Kristensen - One of the best experts on this subject based on the ideXlab platform.

  • dual nicotinic acetylcholine receptor α4β2 antagonists α7 agonists synthesis docking studies and pharmacological evaluation of Tetrahydroisoquinolines and tetrahydroisoquinolinium salts
    Journal of Medicinal Chemistry, 2018
    Co-Authors: François Crestey, Anders A. Jensen, Christian Soerensen, Charlotte Busk Magnus, Jesper T. Andreasen, Günther H. J. Peters, Jesper L. Kristensen
    Abstract:

    We describe the synthesis of Tetrahydroisoquinolines and tetrahydroisoquinolinium salts together with their pharmacological properties at various nicotinic acetylcholine receptors. In general, the compounds were α4β2 nAChR antagonists, with the tetrahydroisoquinolinium salts being more potent than the parent tetrahydroisoquinoline derivatives. The most potent α4β2 antagonist, 6c, exhibited submicromolar binding Ki and functional IC50 values and high selectivity for this receptor over the α4β4 and α3β4 nAChRs. Whereas the (S)-6c enantiomer was essentially inactive at α4β2, (R)-6c was a slightly more potent α4β2 antagonist than the reference β2-nAChR antagonist DHβE. The observation that the α4β2 activity resided exclusively in the (R)-enantiomer was in full agreement with docking studies. Several of tetrahydroisoquinolinium salts also displayed agonist activity at the α7 nAChR. Preliminary in vivo evaluation revealed antidepressant-like effects of both (R)-5c and (R)-6c in the mouse forced swim test, suppo...

  • Dual Nicotinic Acetylcholine Receptor α4β2 Antagonists/α7 Agonists: Synthesis, Docking Studies, and Pharmacological Evaluation of Tetrahydroisoquinolines and Tetrahydroisoquinolinium Salts
    2018
    Co-Authors: François Crestey, Anders A. Jensen, Christian Soerensen, Charlotte Busk Magnus, Jesper T. Andreasen, Günther H. J. Peters, Jesper L. Kristensen
    Abstract:

    We describe the synthesis of Tetrahydroisoquinolines and tetrahydroisoquinolinium salts together with their pharmacological properties at various nicotinic acetylcholine receptors. In general, the compounds were α4β2 nAChR antagonists, with the tetrahydroisoquinolinium salts being more potent than the parent tetrahydroisoquinoline derivatives. The most potent α4β2 antagonist, 6c, exhibited submicromolar binding Ki and functional IC50 values and high selectivity for this receptor over the α4β4 and α3β4 nAChRs. Whereas the (S)-6c enantiomer was essentially inactive at α4β2, (R)-6c was a slightly more potent α4β2 antagonist than the reference β2-nAChR antagonist DHβΕ. The observation that the α4β2 activity resided exclusively in the (R)-enantiomer was in full agreement with docking studies. Several of tetrahydroisoquinolinium salts also displayed agonist activity at the α7 nAChR. Preliminary in vivo evaluation revealed antidepressant-like effects of both (R)-5c and (R)-6c in the mouse forced swim test, supporting the therapeutic potential of α4β2 nAChR antagonists for this indication

Kimihiro Nakano - One of the best experts on this subject based on the ideXlab platform.

Yun Liang - One of the best experts on this subject based on the ideXlab platform.